Pilot Imaging Study for Leukemia and Myeloma
This study is looking at a special type of imaging called 18F FLT PET/CT scans to see if it can help doctors better understand how well treatments are working for certain blood cancers. These cancers include acute lymphocytic leukemia, acute myeloid leukemia, ambiguous lineage leukemia or lymphoma, and myeloma. You would have these scans before and after receiving your therapy. The study aims to see if the imaging results match what doctors find through other tests, and if it can help identify how much disease is present. This study is for people aged 4 to 80 who have high-risk, relapsed, or refractory (not responding to treatment) forms of these cancers. The study is currently unclear about its recruitment status and plans to enroll 60 participants.
- Study design
- This is a pilot study designed to evaluate a new imaging technique. It will involve 60 participants with high-risk acute leukemia or myeloma.
- What's involved
- You would undergo 18F FLT PET/CT scans before starting your therapy and again after your therapy, around 28 days later.
- Compensation
- Not stated in the trial record.
- Follow-up
- You would be followed up to 28 days (+/- 3 days) after your treatment to assess the imaging results.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pilot Imaging Study of Leukemia
At a glance
Conditions
Where it's being run
3 sites across 3 statesStudy leadership
- Jennifer Holter, MD · PRINCIPAL_INVESTIGATOR · Stephenson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of 18F FLT signal uptake abnormalities with clinical pathology reports for determining the evidence of hematopoietic disease.day -7 to 10 days pre-treatment and +28 (+/- 3 days) post-treatment
A proportion of patients will undergo 18F FLT imaging before and after immunotherapy or standard therapy for hematopoietic malignant disease. To detect changes in the progression of hematopoietic disease 18F FLT image scans collected pre-treatment (baseline) and post-treatment (follow-up) of patient visit at OUHSC will be compared with clinically validated evidence of hematopoietic malignant disease collected using MRD, molecular, flow and histology techniques.
- A proportion of 18F FLT uptake in a standard region of interest in marrow to objectively identify disease status in patient with hematopoietic cancers.day -7 to 10 days pre-treatment and +28 (+/- 3 days) post-treatment
For proportion of patient the analyses will be compared between two Arms of disease cohort. Arm A to include patients who received immunotherapy (immunotherapy protocol co-enrollment or other immunotherapy), and Arm B: those who received other non-immune therapies to treat their cancers (excludes HSCT). For marrow disease, the intra-medullary pattern and standard unit of uptake (SUV) will be compared pre- and post-treatment between patients in remission clinically versus those with greater disease burden, to determine if 18F FLT uptake correlates with identified clinical relapse.
- Mean differences of 18F FLT uptake to determine extramedullary disease.day -7 to 10 days pre-treatment and +28 (+/- 3 days) post-treatment
For proportion of patient undergoing 18F FLT scan, the extramedullary disease will be identified by comparing the SUV and size of lesions pre- and post-treatment. The comparisons will be done in two arms of disease cohort Arm A, i.e., to include patients who received immunotherapy (immunotherapy protocol co-enrollment or other immunotherapy), and Arm B: those who received other non-immune therapies to treat their cancers (excludes HSCT).